Kura Oncology (NASDAQ:KURA) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Kura Oncology (NASDAQ:KURA) announced its quarterly earnings results on Tuesday. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.04, FiscalAI reports. The business had revenue of $22.84 million for the quarter, compared to analysts’ expectations of $24.94 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.

Here are the key takeaways from Kura Oncology’s conference call:

• KOMZIFTI net product revenue rose 53% sequentially to $13.9 million, while new patient starts increased 30% and total prescriptions rose 65%. Kura said it retained a majority share of new menin-inhibitor starts and had expanded to 170 prescribing accounts.
• Kura reported eight ziftomenib abstracts at ASH, including first clinical data on combinations with FLT3 inhibitors. Its phase III frontline KOMET-017 program remains on track, with first topline results from the intensive-chemotherapy study expected in 2028.
• Kura said it aligned with the FDA on a single-arm study intended to support full approval of darlifarnib for HRAS-mutant salivary gland cancer. The company plans to begin the approximately 40-patient study in the first half of 2027, while acknowledging the path depends on clinical results.
• Kura ended September with $492 million in cash and investments and received $50 million in debt funding plus a $5 million equity investment under an Oberland agreement that provides up to $300 million. Management expects cash resources, financing proceeds, and anticipated partner payments to fund its current plan beyond the 2028 ziftomenib topline milestone.
• Collaboration revenue guidance for 2026 was revised to $40 million–$45 million; Kura maintained its $90 million–$110 million annual outlook for 2027 and 2028. The company noted that collaboration revenue reflects accounting recognition and not the timing of cash receipts.

Kura Oncology Price Performance

KURA opened at $7.57 on Wednesday. Kura Oncology has a 12 month low of $6.75 and a 12 month high of $13.90. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71. The stock has a market cap of $673.43 million, a P/E ratio of -2.25 and a beta of 0.56. The stock’s 50 day moving average price is $10.49 and its 200 day moving average price is $9.78.

Analyst Ratings Changes

KURA has been the subject of a number of analyst reports. Wedbush boosted their price objective on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research report on Wednesday, October 14th. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research note on Wednesday, October 14th. JPMorgan Chase & Co. assumed coverage on shares of Kura Oncology in a report on Thursday, October 1st. They set an “overweight” rating and a $30.00 price target for the company. Finally, Raymond James Financial set a $24.00 price target on shares of Kura Oncology in a research report on Monday, August 24th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $25.35.

Key Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KOMZIFTI (ziftomenib) net product revenue rose 53% sequentially to $13.9 million. New patient starts increased 30%, prescriptions grew 65%, and the drug held a majority share of new starts in its market—evidence of commercial momentum. Kura Oncology Q3 2026 results and corporate update
• Positive Sentiment: The quarterly loss narrowed year over year: Kura reported a loss of $0.78 per share, better than consensus estimates of roughly $0.82–$0.83 and a $0.85 loss a year earlier. Zacks Q3 earnings report
• Positive Sentiment: Kura said the FDA is aligned with a planned approximately 40-patient darlifarnib study in HRAS-mutated salivary gland cancer, targeted to begin in the first half of 2027. It also reported eight abstracts accepted for ASH 2026, including two oral presentations. Kura Oncology Q3 2026 results and corporate update
• Neutral Sentiment: Kura reported $492.1 million in cash, cash equivalents and short-term investments, with anticipated collaboration payments and access to up to $300 million in additional financing capacity. This supports development, although the company continues to incur substantial losses. Kura Oncology Q3 2026 results and corporate update
• Negative Sentiment: Revenue of $22.84 million, though higher as KOMZIFTI sales expanded, missed analyst expectations of about $24.94 million. The company remains unprofitable, so continued commercial growth will be important to offset development costs. Kura Oncology Q3 loss narrows, revenue rises

Insider Activity

In other Kura Oncology news, insider Brian Powl sold 15,430 shares of the business’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total transaction of $165,872.50. Following the completion of the transaction, the insider owned 136,819 shares in the company, valued at approximately $1,470,804.25. The trade was a 10.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Thomas Doyle sold 4,607 shares of the stock in a transaction on Monday, September 28th. The stock was sold at an average price of $10.50, for a total value of $48,373.50. Following the completion of the transaction, the senior vice president directly owned 142,428 shares of the company’s stock, valued at approximately $1,495,494. The trade was a 3.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 153,881 shares of company stock worth $1,708,183 over the last ninety days. 7.60% of the stock is currently owned by company insiders.

Kura Oncology Company Profile

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.